Caliper Driven licensing program now offers over 335 U.S. patents.

Monogram Biosciences has licensed most of its microfluidics patent portfolio to Caliper Life Sciences on an exclusive basis. The addition of this IP brings Caliper’s patent estate available for licensing under the Caliper Driven licensing program includes over 335 U.S. patents.

“Microfluidics technology is gaining mainstream market adoption,” remarks Kevin Hrusovsky, CEO of Caliper Life Sciences. “It is a next-generation experimentation platform offering data quality, workflow integration, and scalability for critical research and diagnostic applications. By incorporating Monogram’s microfluidic patent estate into our own, we are able to expand the overall breadth and versatility of the applications that we can now pursue—either on our own or with partners through our Caliper Driven program.”

The intellectual property (IP) licensed to Caliper originates from ACLARA BioSciences, which merged with Monogram in 2004.

Under the terms of the license agreement, Monogram retains the right to practice the licensed microfluidics IP for use with its eTag technology.

Previous articleGPC Consolidates Drug Discovery Activities to Munich Site
Next articleACT Bolsters IP Portfolio with hESC Technology from Wisconsin Alumni Research Foundation